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Background
Tumor necrosis factor receptor-associated periodic syn-
drome (TRAPS) is a rare autoinflammatory disorder
caused by TNFRSF1A mutations. The symptoms of
TRAPS are various and often unspecific. The R92Q var-
iant is considered to be a low penetration mutation with
mild phenotype.
Objective
To analyze the clinical course of a woman carrying the
R92Q Mutation and presenting with rheumatic disease
and some symptoms consistent with autoinflammatory
syndrome.
Methods
A woman was identified as carrying the p.Arg121Gln-/
R92Q mutation in the TNFRSF1A gene and presenting
with autoinflammatory symptoms.
Results
The patient was hospitalized 3 times with abdominal
pain elevated CRP and fever. She was presumed to have
recurrent abdominal infections and treated with antibio-
tics. The laboratory tests showed no increase on leuko-
cytes counts but elevated CRP (to198mg/l), which
normalized after a few days. CT-scans and 2 ultrasounds
were performed, which showed signs of panniculitis of
the abdominal fat, but no other pathology. Even a diag-
nostic laparoscopy was performed with no further
results. The patient had a history of recurrent fever
(39°C), arthralgia, myalgia, abdominal pain, diarrhoe,
backpain, hyperkeratotic skin lesions and constantly ele-
vated ESR and CRP. Interestingly, ANA and dsDNS anti-
bodies had been showed to be elevated over many years.
The patient was first diagnosed an overlap connective
tissue disease/undifferentiated SpA. Later on, periodic
fever syndrome was suspected and the genetic tests per-
formed. The genetic analysis showed the presence of p.
Arg121Gln-/R92Q mutation. When treated with methor-
exate and etanercept the patient showed improvement of
most symptoms including arthralgia, back pain and skin
disease. ANA and dsDNS antibodies turned negative but
CRP and ESR remained elevated. The fever episodes were
persisting so that etanercept was stopped and the treat-
ment with IL-1 antagonist startet. Under the treatment
with anakinra 100 mg every second day, we observed an
improvement of fever and abdominal symptoms although
no remission. The skin lesions, the arthralgia and back
pain returned. Anakinra dosis was enhanced to daily appli-
cations of 100 mg with further improvement of the autoin-
flammatory symptoms. Back pain, arthralgia and skin
lesions persist.
Conclusion
Our findings suggest that the R92Q mutation is influen-
cing the phenotype of the rheumatic disease in this patient
and seams to be responsible for part of the presenting
symptoms.
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